Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound

Published

News published by Spexis concerning murepavadin, administered via an optimized investigational eFlow® Technology nebulizer.
 

Read the press release

Back to overview